Clinical Trial Update: To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update announces completion of Phase 1/2 evaluating GC1111 for Hunter syndrome (Mucopolysaccharidosis type II) focusing on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Ii

Drugs mentioned

• GC1111 (recombinant human iduronate-2-sulfatase)

Snippet

Sponsor: Green Cross Corporation | Conditions: Mucopolysaccharidosis II | Phase 1, Phase 2 | Status: COMPLETED